Preclinical Meta-Analysis of Moringa Oleifera for Peptic Ulcer Disease

Aggregating results from a systematic review and meta-analysis of 11 preclinical studies involving 268 animals, evaluating the therapeutic effect of Moringa oleifera on peptic ulcer disease. The analysis includes pooled effect sizes, subgroup analyses by dose and comparator, and assessments of heterogeneity and publication bias.

Use Cases

• Analyze the relationship between Moringa oleifera dose and the Standard Mean Difference (SMD) in ulcer index reduction across 11 studies.
• Compare the therapeutic effect of Moringa oleifera against standard drugs versus basal controls using the SMD and confidence intervals from subgroup analyses.
• Examine study heterogeneity using the I² statistic and publication bias via Egger’s regression results included in the meta-analysis.
• Assess the quality of included preclinical studies using the SYRCLE quality scores, which range from 8 to 9.

Strengths

• Includes data from 11 studies involving 268 animals, providing a consolidated preclinical evidence base.
• Reports quantitative meta-analysis results including Standard Mean Difference (SMD), confidence intervals, p-values, and I² heterogeneity statistics.
• Systematic review was registered under identifier CRD420251080346, following a structured methodology.

Limitations

• The dataset is small in scale at 73.3 KB, containing only summary-level meta-analysis results, not raw experimental data.
• Findings are limited to preclinical (rodent) studies; no clinical trial data is included, limiting direct human applicability.
• The meta-analysis noted methodological heterogeneity among the included studies.

Provenance

Source

figshare, authored by Saheed Olatunbosun Akiode.

Collection Method

Systematic review and meta-analysis of eligible studies from PubMed, CINAHL, Scopus, Web of Science, and the Cochrane Library.

Time Range

Literature search from database inception to August 2025.

Freshness

Last updated on 2026-03-20, with literature search up to August 2025.